iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL von Hallek, Michael, Cheson, Bruce D., Catovsky, Daniel, Caligaris-Cappio, Federico, Dighiero, Guillermo, Döhner, Hartmut, Hillmen, Peter, Keating, Michael, Montserrat, Emili, Chiorazzi, Nicholas, Stilgenbauer, Stephan, Rai, Kanti R., Byrd, John C., Eichhorst, Barbara, O'Brien, Susan, Robak, Tadeusz, Seymour, John F., Kipps, Thomas J.

Volltext

The B-cell receptor signaling pathway as a therapeutic target in CLL von Woyach, Jennifer A., Johnson, Amy J., Byrd, John C.

Volltext

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial von Byrd, John C, Hillmen, Peter, Ghia, Paolo, Kater, Arnon P, Chanan-Khan, Asher, Furman, Richard R, O'Brien, Susan, Yenerel, Mustafa Nuri, Illés, Arpad, Kay, Neil, Garcia-Marco, Jose A, Mato, Anthony, Pinilla-Ibarz, Javier, Seymour, John F, Lepretre, Stephane, Stilgenbauer, Stephan, Robak, Tadeusz, Rothbaum, Wayne, Izumi, Raquel, Hamdy, Ahmed, Patel, Priti, Higgins, Kara, Sohoni, Sophia, Jurczak, Wojciech

Volltext

Hypertension and incident cardiovascular events following ibrutinib initiation von Dickerson, Tyler, Wiczer, Tracy, Waller, Allyson, Philippon, Jennifer, Porter, Kyle, Haddad, Devin, Guha, Avirup, Rogers, Kerry A., Bhat, Seema, Byrd, John C., Woyach, Jennifer A., Awan, Farrukh, Addison, Daniel

Volltext

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation von Buhimschi, Alexandru D, Armstrong, Haley A, Toure, Momar, Jaime-Figueroa, Saul, Chen, Timothy L, Lehman, Amy M, Woyach, Jennifer A, Johnson, Amy J, Byrd, John C, Crews, Craig M

Volltext

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia von Byrd, John C, Harrington, Bonnie, O’Brien, Susan, Jones, Jeffrey A, Schuh, Anna, Devereux, Steve, Chaves, Jorge, Wierda, William G, Awan, Farrukh T, Brown, Jennifer R, Hillmen, Peter, Stephens, Deborah M, Ghia, Paolo, Barrientos, Jacqueline C, Pagel, John M, Woyach, Jennifer, Johnson, Dave, Huang, Jane, Wang, Xiaolin, Kaptein, Allard, Lannutti, Brian J, Covey, Todd, Fardis, Maria, McGreivy, Jesse, Hamdy, Ahmed, Rothbaum, Wayne, Izumi, Raquel, Diacovo, Thomas G, Johnson, Amy J, Furman, Richard R

Volltext

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience von O'Brien, Susan, Furman, Richard R., Coutre, Steven, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Wierda, William, Jones, Jeffrey, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Luan, Ying, James, Danelle F., Chu, Alvina D., Byrd, John C.

Volltext

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables von Roberts, Andrew W., Ma, Shuo, Kipps, Thomas J., Coutre, Steven E., Davids, Matthew S., Eichhorst, Barbara, Hallek, Michael, Byrd, John C., Humphrey, Kathryn, Zhou, Lang, Chyla, Brenda, Nielsen, Jacqueline, Potluri, Jalaja, Kim, Su Young, Verdugo, Maria, Stilgenbauer, Stephan, Wierda, William G., Seymour, John F.

Volltext

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab von Byrd, John C., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine S., Mulligan, Stephen P., Jaeger, Ulrich, Barr, Paul M., Furman, Richard R., Kipps, Thomas J., Thornton, Patrick, Moreno, Carol, Montillo, Marco, Pagel, John M., Burger, Jan A., Woyach, Jennifer A., Dai, Sandra, Vezan, Remus, James, Danelle F., Brown, Jennifer R.

Volltext

Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies von Guha, Avirup, Derbala, Mohamed H., Zhao, Qiuhong, Wiczer, Tracy E., Woyach, Jennifer A., Byrd, John C., Awan, Farrukh T., Addison, Daniel

Volltext

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials von Brown, Jennifer R, Moslehi, Javid, O'Brien, Susan, Ghia, Paolo, Hillmen, Peter, Cymbalista, Florence, Shanafelt, Tait D, Fraser, Graeme, Rule, Simon, Kipps, Thomas J, Coutre, Steven, Dilhuydy, Marie-Sarah, Cramer, Paula, Tedeschi, Alessandra, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C, Howes, Angela, Todd, Michael, Vermeulen, Jessica, James, Danelle F, Clow, Fong, Styles, Lori, Valentino, Rudy, Wildgust, Mark, Mahler, Michelle, Burger, Jan A

Volltext

Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function von Stiff, Andrew, Trikha, Prashant, Mundy-Bosse, Bethany, McMichael, Elizabeth, Mace, Thomas A, Benner, Brooke, Kendra, Kari, Campbell, Amanda, Gautam, Shalini, Abood, David, Landi, Ian, Hsu, Vincent, Duggan, Megan, Wesolowski, Robert, Old, Matthew, Howard, John Harrison, Yu, Lianbo, Stasik, Nancy, Olencki, Thomas, Muthusamy, Natarajan, Tridandapani, Susheela, Byrd, John C, Caligiuri, Michael, Carson, William E

Volltext

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia von Woyach, Jennifer A, Ruppert, Amy S, Guinn, Daphne, Lehman, Amy, Blachly, James S, Lozanski, Arletta, Heerema, Nyla A, Zhao, Weiqiang, Coleman, Joshua, Jones, Daniel, Abruzzo, Lynne, Gordon, Amber, Mantel, Rose, Smith, Lisa L, McWhorter, Samantha, Davis, Melanie, Doong, Tzyy-Jye, Ny, Fan, Lucas, Margaret, Chase, Weihong, Jones, Jeffrey A, Flynn, Joseph M, Maddocks, Kami, Rogers, Kerry, Jaglowski, Samantha, Andritsos, Leslie A, Awan, Farrukh T, Blum, Kristie A, Grever, Michael R, Lozanski, Gerard, Johnson, Amy J, Byrd, John C

Volltext

Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model von Halley, Patrick D., Lucas, Christopher R., McWilliams, Emily M., Webber, Matthew J., Patton, Randy A., Kural, Comert, Lucas, David M., Byrd, John C., Castro, Carlos E.

Volltext

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib von Woyach, Jennifer A, Furman, Richard R, Liu, Ta-Ming, Ozer, Hatice Gulcin, Zapatka, Marc, Ruppert, Amy S, Xue, Ling, Li, Daniel Hsieh-Hsin, Steggerda, Susanne M, Versele, Matthias, Dave, Sandeep S, Zhang, Jenny, Yilmaz, Ayse Selen, Jaglowski, Samantha M, Blum, Kristie A, Lozanski, Arletta, Lozanski, Gerard, James, Danelle F, Barrientos, Jacqueline C, Lichter, Peter, Stilgenbauer, Stephan, Buggy, Joseph J, Chang, Betty Y, Johnson, Amy J, Byrd, John C

Volltext

DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia von Oakes, Christopher C, Seifert, Marc, Assenov, Yassen, Gu, Lei, Przekopowitz, Martina, Ruppert, Amy S, Wang, Qi, Imbusch, Charles D, Serva, Andrius, Koser, Sandra D, Brocks, David, Lipka, Daniel B, Bogatyrova, Olga, Weichenhan, Dieter, Brors, Benedikt, Rassenti, Laura, Kipps, Thomas J, Mertens, Daniel, Zapatka, Marc, Lichter, Peter, Döhner, Hartmut, Küppers, Ralf, Zenz, Thorsten, Stilgenbauer, Stephan, Byrd, John C, Plass, Christoph

Volltext

Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling von Yeh, Yuh-Ying, Ozer, Hatice Gulcin, Lehman, Amy M., Maddocks, Kami, Yu, Lianbo, Johnson, Amy J., Byrd, John C.

Volltext

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 von Herman, Sarah E.M., Gordon, Amber L., Hertlein, Erin, Ramanunni, Asha, Zhang, Xiaoli, Jaglowski, Samantha, Flynn, Joseph, Jones, Jeffrey, Blum, Kristie A., Buggy, Joseph J., Hamdy, Ahmed, Johnson, Amy J., Byrd, John C.

Volltext

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody von Benson, Don M., Bakan, Courtney E., Mishra, Anjali, Hofmeister, Craig C., Efebera, Yvonne, Becknell, Brian, Baiocchi, Robert A., Zhang, Jianying, Yu, Jianhua, Smith, Megan K., Greenfield, Carli N., Porcu, Pierluigi, Devine, Steven M., Rotem-Yehudar, Rinat, Lozanski, Gerard, Byrd, John C., Caligiuri, Michael A.

Volltext

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia von Rogers, Kerry A., Huang, Ying, Ruppert, Amy S., Awan, Farrukh T., Heerema, Nyla A., Hoffman, Corinne, Lozanski, Gerard, Maddocks, Kami J., Moran, Mollie E., Reid, Mark A., Lucas, Margaret, Woyach, Jennifer A., Whitlow, W. Thomas, Jones, Jeffrey A., Byrd, John C.

Volltext